Announcement • Mar 17
Access Bio, Inc., Annual General Meeting, Mar 31, 2026 Access Bio, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 16, magokjungang 8-ro 1-gil, gangseo-gu, seoul South Korea Announcement • Jan 20
Access Bio, Inc. (KOSDAQ:A950130) agreed to acquire an unknown minority stake in Rfbio Co., Ltd. from RFTech Co., Ltd. (KOSDAQ:A061040) Access Bio, Inc. (KOSDAQ:A950130) agreed to acquire a 8.99% stake in Rfbio Co., Ltd. from RFTech Co., Ltd. (KOSDAQ:A061040) for KRW 20 billion on January 19, 2026. A cash consideration valued at KRW 21960 per share will be paid by Access Bio, Inc. The deal has been approved by the Board of directors of RFTech Co., Ltd. If the disposal of this subsidiary's stock and the paid-in capital increase promoted by the major subsidiary (RF Bio Co., Ltd.) are completed, the largest shareholder of RF Bio Co., Ltd. will change from RF Tech Co., Ltd. to Access Bio, Inc.
The expected completion of the transaction is March 27, 2026. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩137.4b market cap, or US$97.9m). Board Change • Sep 29
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director JinSu Jeong was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Jul 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings have declined by 7.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 22
Full year 2024 earnings released: ₩14.00 loss per share (vs ₩91.00 loss in FY 2023) Full year 2024 results: ₩14.00 loss per share (improved from ₩91.00 loss in FY 2023). Revenue: ₩112.5b (down 68% from FY 2023). Net loss: ₩347.6m (loss narrowed 89% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Announcement • Mar 13
Access Bio, Inc., Annual General Meeting, Mar 26, 2025 Access Bio, Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 16, magokjungang 8-ro 1-gil, gangseo-gu, seoul South Korea New Risk • Aug 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩91.00 loss per share (vs ₩10,051 profit in FY 2022) Full year 2023 results: ₩91.00 loss per share (down from ₩10,051 profit in FY 2022). Revenue: ₩348.6b (down 66% from FY 2022). Net loss: ₩3.17b (down 101% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 16% per year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩871 per share at 8.8% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 8.8%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.6%). New Risk • Dec 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 399% Paying a dividend despite having no free cash flows. High level of non-cash earnings (83% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (1.9% net profit margin). Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to ₩11,790, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total loss to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩10,350, the stock trades at a trailing P/E ratio of 42.3x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total loss to shareholders of 63% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩10,450, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total loss to shareholders of 62% over the past three years. New Risk • Aug 25
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 121% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 339% Paying a dividend despite having no free cash flows. High level of non-cash earnings (121% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (2.1% net profit margin). Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩9,110, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total loss to shareholders of 26% over the past three years. New Risk • Jul 20
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 10% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. New Risk • Jun 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • May 21
First quarter 2023 earnings released: EPS: ₩1,212 (vs ₩7,929 in 1Q 2022) First quarter 2023 results: EPS: ₩1,212 (down from ₩7,929 in 1Q 2022). Revenue: ₩239.4b (down 70% from 1Q 2022). Net income: ₩41.2b (down 85% from 1Q 2022). Profit margin: 17% (down from 35% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 19
Third quarter 2022 earnings released: ₩457 loss per share (vs ₩532 profit in 3Q 2021) Third quarter 2022 results: ₩457 loss per share (down from ₩532 profit in 3Q 2021). Revenue: ₩12.4b (down 70% from 3Q 2021). Net loss: ₩16.2b (down 186% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 81% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improved over the past week After last week's 27% share price gain to ₩20,600, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 482% over the past three years. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improved over the past week After last week's 22% share price gain to ₩19,550, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 390% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 26% share price gain to ₩19,500, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 352% over the past three years. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment improved over the past week After last week's 21% share price gain to ₩20,450, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 318% over the past three years. Reported Earnings • Aug 23
Second quarter 2021 earnings released: ₩604 loss per share (vs ₩12.00 profit in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: ₩13.0b (up 30% from 2Q 2020). Net loss: ₩21.3b (down ₩21.5b from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 54% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment deteriorated over the past week After last week's 36% share price decline to ₩18,000, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 322% over the past three years. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 19% share price gain to ₩34,750, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total returns to shareholders of 685% over the past three years. Announcement • Jun 30
Atomo Diagnostics Limited Receives FDA Clearance for Covid-19 Antibody Test Atomo Diagnostics Limited announced that Access Bio Inc. has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for point-of-care use of its CareStartTM EZ COVID-19 IgM/IgG test. CareStart EZ COVID-19 IgM/IgG is a rapid antibody test made by combining an integrated device developed by Atomo and a rapid COVID-19 antibody test strip from Access Bio. Atomo announced on 28 July 2020 that it had entered into an agreement to supply Access Bio with its unique, integrated rapid diagnostic test (RDT) devices for use in North America with Access Bio's rapid test strip for detection of antibodies to COVID-19 subject to FDA clearance. Atomo thereafter announced, on 29 September 2020, the expansion of this rapid test partnership to grant Atomo non-exclusive rights to market and distribute Access Bio's COVID-19 rapid antigen test in Australia, New Zealand and India, subject to obtaining the required regulatory approvals in each jurisdiction. This EUA allows sales of the CareStart EZ COVID-19 IgM/IgG test for use in point-of-care settings like doctors' offices, hospitals and emergency rooms in the United States. Atomo and Access Bio are in discussions regarding their COVID-19 rapid test commercial arrangements and Atomo will keep the market informed as to any material developments. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 15% share price gain to ₩23,550, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 388% over the past three years. Valuation Update With 7 Day Price Move • May 13
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩26,700, the stock trades at a trailing P/E ratio of 18.7x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 418% over the past three years. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 36% share price gain to ₩25,500, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 386% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 26% share price gain to ₩16,500, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years. Is New 90 Day High Low • Feb 23
New 90-day low: ₩16,750 The company is down 14% from its price of ₩19,500 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. Announcement • Feb 10
Access Bio, Inc., Annual General Meeting, Mar 25, 2021 Access Bio, Inc., Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time. Location: 2nd floor of Wells Bio Building, 16, Magok Jungang 8-ro 1-gil Seoul South Korea Is New 90 Day High Low • Jan 11
New 90-day low: ₩19,400 The company is down 42% from its price of ₩33,400 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. Announcement • Dec 19
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests Intrivo Diagnostics announced that it will begin national distribution and commercialization of diagnostic testing products developed by New Jersey-based testing manufacturer, Access Bio, Inc. through McKesson Medical-Surgical. McKesson joins Concordance Healthcare Solutions and NDC, Inc. as key national partners within the Healthcare Supply Chain to help bring the CareStart™ line of COVID-19 testing products to the US market. As Access Bio’s exclusive US commercialization partner, Intrivo’s new channel agreements will expand the supply chain for the CareStart™ line of COVID-19 testing products across the country, ensuring greater access to testing supplies for healthcare providers and organizations. To date, Access Bio has received FDA Emergency Use Authorization (EUA) for its RT-PCR test, IgM/IgG antibody test and most recently, a rapid point-of-care (POC) antigen test. The CareStart™ COVID-19 antigen test is a lateral-flow immunochromatographic assay capable of producing results within 10 minutes of being administered with 88.4% sensitivity and 100% specificity. The test is a self-contained, single-use product designed to detect extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal specimens collected from individuals suspected of being infected with COVID-19 or exposed to COVID-19. The assay includes a swab, a vial of extraction solution and a cassette the size of a small flash drive. A positive test result is indicated by a visible line in the cassette and doesn’t require any special technical training to use. Each kit can administer up to 20 antigen tests. McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. From providing technologies and delivery solutions, to contract and sales support, their involvement will help Intrivo Diagnostics and Access Bio guarantee delivery of CareStart™ testing solutions safely and cost-effectively throughout the US. Established in 2002, Access Bio has a proven track record of releasing top-performing products, including its CareStart™ Malaria Rapid Diagnostic Test (RDT). Announcement • Dec 05
Intrivo Diagnostics Inks National Distribution Agreements with Concordance Healthcare Solutions and NDC for Access Bio CareStart Covid-19 Tests Intrivo Diagnostics announced that it will begin national distribution and commercialization of diagnostic testing products developed by Access Bio, Inc. through Concordance Healthcare Solutions and NDC, Inc. As Access Bio’s exclusive US commercialization partner, Intrivo’s new channel agreements will expand the supply chain for the CareStart line of COVID-19 testing products across the country, ensuring greater access to testing supplies for healthcare providers and organizations. To date, Access Bio has received FDA Emergency Use Authorization (EUA) for its RT-PCR test, IgM/IgG antibody test and most recently, a rapid point-of-care (POC) antigen test. The CareStart COVID-19 antigen test is a lateral-flow immunochromatographic assay capable of producing results within 10 minutes of being administered with 88.4% sensitivity and 100% specificity. The test is a self-contained, single-use product designed to detect extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal specimens collected from individuals suspected of being infected with COVID-19 or exposed to COVID-19. The assay includes a swab, a vial of extraction solution and a cassette the size of a small flash drive. A positive test result is indicated by a visible line in the cassette and doesn’t require any special technical training to use. Each kit can administer up to 20 antigen tests. Concordance Healthcare Solutions and NDC, Inc. are proven leaders in distributing medical and laboratory products throughout the continuum of care. From providing technologies and delivery solutions, to contract and sales support, their involvement will help Intrivo Diagnostics and Access Bio guarantee delivery of CareStartTM testing solutions safely and cost-effectively throughout the US. Announcement • Aug 15
Wooridul Pharmaceutical Limited (KOSE:A004720) cancelled the acquisition of 11.6% stake in Access Bio, Inc. (KOSDAQ:A950130) from Youngho Choi. Wooridul Pharmaceutical Limited (KOSE:A004720) signed a contract to acquire 11.6% stake in Access Bio, Inc. (KOSDAQ:A950130) from Youngho Choi for KRW 17 billion on July 3, 2019. Wooridul Pharmaceutical Limited will acquire 3.1 million shares at KRW 5430 per share. As of August 14, 2018, Wooridul Pharmaceutical Limited will acquire 9.83% stake in Access Bio, Inc. from Youngho Choi for KRW 13.9 billion. Wooridul Pharmaceutical Limited will acquire 2.66 million shares at KRW 5210 per share. Wooridul Pharmaceutical Limited will acquire 2.1 million share on July 3, 2019 and 1.025 million on August 21, 2019. In related transaction, Wooridul Pharmaceutical Limited agreed to acquire 2.1% stake in Access Bio from Youngho Choi and others on July 3, 2019. Combined consideration for both acquisition is KRW 20 billion of which KRW 10.5 billion will be paid on July 5, 2019 and KRW 9.5 billion will be paid on August 21, 2019. As of August 14, 2018, first payment of KRW 10.5 billion paid on July 5, 2019 and remaining on KRW 3.35 billion on August 21, 2019. Scheduled change date is August 21, 2019.
Wooridul Pharmaceutical Limited (KOSE:A004720) cancelled the acquisition of 11.6% stake in Access Bio, Inc. (KOSDAQ:A950130) from Youngho Choi on July 3, 2020. 
